FIELD: clinical pharmacology; may be used for treatment of ischemic affections of brain. SUBSTANCE: invention recommends to use known compound, ammonium succinate, as a corrector of disturbances in blood supply and brain metabolism. Antiischemic effect of ammonium succinate is explained by intensified blood supply of brain, as well as its antihypoxic and antiacidotic activity. Preparation normalizes succinate-dependent energy generation of cerebral mitochondria. EFFECT: enhanced efficiency in treatment of patients effected with cerebral ischemia. 7 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTIINFLAMMATORY AGENT | 1994 |
|
RU2118161C1 |
β-HYDROXY ETHYLAMINIUM NICOTINATE DERIVATIVES HAVING ANTIISCHENIC ACTIVITY | 1993 |
|
RU2124502C1 |
METHOD FOR MODELLING CEREBRAL ISCHEMIA DISEASE AGGRAVATED BY HEMISPHERE ASYMMETRY PHENOMENA | 1993 |
|
RU2083000C1 |
MAGNESIUM BIS (2-AMINOETHANESULFONIC ACID)-BUTANEDIOATE, WHICH HAS ANTIHYPOXIC, NEUROPROTECTIVE AND HYPOCOAGULANT ACTIVITY | 2017 |
|
RU2671982C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS OF CARDIOVASCULAR, TRAUMATIC, TOXIC, HYPOXIC AND AUTOIMMUNE GENESIS | 2010 |
|
RU2445106C1 |
MEDICINAL COMPOSITION | 2001 |
|
RU2213562C2 |
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
MEDICATION FOR TREATING CEREBRAL CIRCULATION DISORDERS AND BRAIN TRAUMAS | 2012 |
|
RU2554502C9 |
PHARMACEUTICAL COMPOSITIONS CONTAINING S-AMLODIPINE NICOTINATE AND USING THEM IN TREATING CEREBROVASCULAR DISORDERS | 2012 |
|
RU2516922C2 |
2-ETHYL-6-METHYL-3-HYDROXYLIRIDINIUMHYDROXYBUTANEDIOAT EXPRESSING ANTI-ISHEMIC, CEREBROPROTECTIVE, NEUROTROPIC AND LIPID-REGULATING ACTIVITY, PHARMACEUTICAL COMPOSITIONS AND MEDICAL PRODUCT | 2008 |
|
RU2377237C1 |
Authors
Dates
1998-04-10—Published
1994-11-22—Filed